Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Internet-Based Exercise and Diet Support in Prostate Cancer Survivors

Not Applicable

Completed

Conditions: Cancer Survivor
Prostate Carcinoma

Interventions: Behavioral: Written Information
Behavioral: Prescription
Behavioral: Technology
Behavioral: Coaching

First Posted Date: 2018-01-23

Last Posted Date: 2020-07-29

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 206

Registration Number: NCT03406013

Locations: 🇺🇸
UCSF Medical Center-Mount Zion, San Francisco, California, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Liposarcoma
Malignant Abdominal Neoplasm
Malignant Retroperitoneal Neoplasm
Malignant Scrotal Neoplasm
Malignant Solid Neoplasm
Malignant Spermatic Cord Neoplasm

Interventions: Drug: Eribulin Mesylate
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2017-12-04

Last Posted Date: 2024-03-19

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03361436

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: Ferumoxytol
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2017-11-20

Last Posted Date: 2024-04-17

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 56

Registration Number: NCT03347617

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Phase 2

Terminated

Conditions: Lung Carcinoma Metastatic in the Brain
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Ferumoxytol
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2017-10-30

Last Posted Date: 2022-08-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03325166

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

Early Phase 1

Terminated

Conditions: Locally Advanced Rectal Carcinoma
Stage III Rectal Cancer AJCC v7
Stage IIIA Rectal Cancer AJCC v7
Stage IIIB Rectal Cancer AJCC v7
Stage IIIC Rectal Cancer AJCC v7

Interventions: Procedure: Contrast-enhanced Magnetic Resonance Imaging
Drug: Ferumoxytol

First Posted Date: 2017-09-12

Last Posted Date: 2021-09-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03280277

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

Phase 2

Recruiting

Conditions: Cranial Nerve Disorder
Central Nervous System Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Drug: Ferumoxytol
Drug: Gadolinium
Procedure: Magnetic Resonance Imaging

First Posted Date: 2017-09-01

Last Posted Date: 2024-08-15

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 150

Registration Number: NCT03270059

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer

Not Applicable

Withdrawn

Conditions: Head and Neck Carcinoma

Interventions: Other: Best Practice
Other: Laboratory Biomarker Analysis
Dietary Supplement: Nutritional Intervention

First Posted Date: 2017-08-24

Last Posted Date: 2020-02-25

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT03261180

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors

Phase 2

Withdrawn

Conditions: Brain Neoplasm

Interventions: Drug: Ferumoxytol
Procedure: Magnetic Resonance Imaging

First Posted Date: 2017-07-31

Last Posted Date: 2021-11-10

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT03234309

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

Not Applicable

Completed

Conditions: Lung Carcinoma
Prostate Carcinoma
Caregiver
Head and Neck Carcinoma
Breast Carcinoma
Tobacco Use

Interventions: Other: Communication Skills Training
Other: Medical Chart Review
Other: Questionnaire Administration
Other: Tobacco Cessation Counseling

First Posted Date: 2017-05-01

Last Posted Date: 2021-03-05

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03135782

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

Phase 2

Completed

Conditions: Malignant Neoplasm

Interventions: Drug: Netupitant
Drug: Palonosetron Hydrochloride
Other: Questionnaire Administration

First Posted Date: 2017-03-31

Last Posted Date: 2021-07-12

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 43

Registration Number: NCT03097588

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy